Stay updated on Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page
- ChecktodayChange DetectedThe page has updated its dates, removing some past estimates and adding confirmed dates for events in June 2025.SummaryDifference0.9%
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check58 days agoChange DetectedThe page has been updated to reflect a new trial, SAKK 07/17, focusing on Renal Cell Carcinoma, with a revision to version 2.15.0. Significant details about the previous immunotherapy trial have been removed, indicating a shift in focus.SummaryDifference44%
- Check65 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Cell Carcinoma Clinical Trial page.